Neuren Media and Analyst Coverage, page-1719

Not sure I understand your question - excess of IGF-1 facilitating in the development of autism?

I think Hottod's point provided evidence that showed the correlation between excess IGF-1 in neonates and Autism.

I asked Gemini to review the papers that Hottod shared and also asked it to review the available information/literature on 2591 and asked whether this information bodes well for Neuren. This is what it said.

"Based on an analysis of the provided scientific papers and information about Neuren Pharmaceuticals' drug candidate NNZ-2591, the papers appear to be favorable for the company and its drug. Here's a breakdown of why:

The first paper, an editorial from the journal Frontiers in Psychiatry titled "Secondary vs. Idiopathic Autism," emphasizes the importance of identifying specific genetic and metabolic causes of autism spectrum disorder (ASD). The authors argue that understanding the biological basis of "secondary" ASD (autism with a known cause) is key to developing targeted and effective treatments. This aligns well with Neuren's strategy of developing NNZ-2591 for specific neurodevelopmental disorders with known genetic origins, such as Pitt-Hopkins, Phelan-McDermid, and Angelman syndromes. The paper validates the overall scientific approach of targeting the underlying biology of these conditions.

The second paper, published in the International Journal of Molecular Sciences, proposes a hypothesis that dysregulation of Insulin-like Growth Factor 1 (IGF-1) plays a significant role in the development of idiopathic ASD. This is highly relevant to Neuren's NNZ-2591, which is a synthetic analog of a breakdown product of IGF-1 and acts as a modulator of the IGF-1 system. This paper provides a strong theoretical foundation for the mechanism of action of NNZ-2591. If, as the paper suggests, the IGF-1 pathway is a key factor in neurodevelopmental disorders, then a drug designed to modulate this pathway is a promising therapeutic candidate.

NNZ-2591 is currently in Phase 2 clinical trials and has already shown positive results for Pitt Hopkins syndrome and Phelan-McDermid syndrome, with a good safety profile. These results, combined with the scientific rationale supported by the two papers, suggest a positive outlook for Neuren and the continued development of NNZ-2591 for a range of neurodevelopmental disorders."